HS1 Antibody

How do I select the most appropriate HS1 antibody for my experimental system?

Methodological Answer:

• Species Specificity: Confirm cross-reactivity using technical specifications. For example, Cell Signaling Technology #4503 detects human HS1 (80 kDa apparent MW), while #3892 targets mouse HS1 .

• Application Suitability: Prioritize antibodies validated for your technique (e.g., Western blotting vs. immunohistochemistry). The GenScript A01630 antibody was validated for immunoprecipitation using lysates from PLB-985 cells .

• Phosphorylation Status: HS1 function depends on tyrosine phosphorylation (e.g., Y378, Y397). Use phospho-specific antibodies if studying activation dynamics .

Validation Protocol:

• Knockout Controls: Compare signal intensity in wild-type vs. HS1-deficient cells (e.g., siRNA knockdown in ES2 ovarian cancer cells) .

• Orthogonal Methods: Cross-validate via qPCR or CRISPR-Cas9 knockout lines .

• Epitope Mapping: Use truncated HS1 mutants to confirm binding regions (e.g., residues 250–300 for GenScript A01630) .

Why do HS1 antibodies show conflicting subcellular localization in cancer studies?

Methodological Answer:
HS1 exhibits context-dependent localization:

• Cytoplasmic in Ovarian Cancer: HS1 promotes invasion via actin remodeling in ES2 and NOE cell lines .

• Nuclear in Leukocytes: Phosphorylated HS1 translocates to the nucleus during T cell activation .

Resolution Strategy:

• Fractionation Assays: Separate nuclear/cytoplasmic lysates (e.g., NE-PER kit) followed by Western blotting .

• Stimulation Conditions: Test localization under varying stimuli (e.g., TCR ligation in T cells) .

What methods ensure accurate HS1 quantification in patient-derived tissues?

Methodological Answer:

• IHC Scoring: Use standardized scales (e.g., H-score) with blinded pathologist review. In ovarian cancer, HS1 positivity correlates with poor survival (HR = 2.1, P < 0.05) .

• Digital Pathology: Apply AI-based tools for pixel density analysis in stromal vs. tumor regions .

• Multiplex Staining: Combine HS1 with markers like Ki-67 or E-cadherin to assess proliferative/invasive phenotypes .

Data Table: HS1 Expression in Ovarian Cancer (n = 171)

Source: PMC6135686

How can I mechanistically link HS1 to metastatic phenotypes?

Methodological Answer:

• siRNA/CRISPR Knockdown: In ES2 ovarian cancer cells, HS1 silencing reduces wound healing by 44% and Matrigel invasion by 62% .

• Rescue Experiments: Re-express wild-type or phosphorylation-deficient HS1 (Y378F/Y397F) to confirm phenotype reversibility .

• Live-Cell Imaging: Track actin dynamics using LifeAct-GFP in HS1-depleted cells .

Critical Controls:

• Off-Target Effects: Use multiple siRNA sequences (e.g., Dharmacon SMARTpool).

• Cortactin Compensation: Test HS1/cortactin double knockouts, as they share actin-regulatory roles .

What techniques resolve HS1 phosphorylation states in signaling studies?

Methodological Answer:

• Phospho-Specific Antibodies: Use clones validated for pY378 or pY397 (e.g., Cell Signaling Technology #3892 for mouse HS1) .

• Kinase Inhibition: Treat cells with Lyn kinase inhibitors (e.g., dasatinib) to block HS1 phosphorylation .

• Mass Spectrometry: Identify novel phosphorylation sites via LC-MS/MS after immunoprecipitation .

Case Study:
In neutrophils, HS1 phosphorylation by Lyn governs chemotaxis. HS1-deficient mice show 70% reduced neutrophil lung infiltration in sepsis models (P < 0.01) .

How do I prevent cross-reactivity between HS1 and cortactin antibodies?

Methodological Answer:

• Epitope Comparison: Cortactin (CTTN) shares 37% homology with HS1 but lacks the C-terminal SH3 domain. Select antibodies targeting non-conserved regions (e.g., HS1 residues 250–300) .

• Preabsorption Tests: Incubate antibodies with recombinant cortactin to confirm specificity .

• Dual Knockdown: Use siRNA against both proteins to isolate individual effects .

What models best study HS1’s role in T cell activation?

Methodological Answer:

• Immune Synapse (IS) Assays: Plate T cells on anti-CD3/CD28-coated coverslips. HS1-deficient T cells show disordered F-actin accumulation at IS .

• Calcium Flux Measurement: Use Fluo-4 AM dye. HS1−/− T cells exhibit 50% reduced Ca²+ influx post-TCR activation .

• Retroviral Reconstitution: Express HS1 mutants (e.g., ΔSH3) in HS1−/− cells to dissect domain functions .

Key Finding:
HS1 tyrosine phosphorylation is required for Vav1 recruitment to IS (r = 0.89, P < 0.001) .

How do I model HS1’s systemic effects in murine sepsis?

Methodological Answer:

• HS1−/− Mice: These exhibit attenuated neutrophil lung infiltration and 40% improved survival in LPS-induced sepsis .

• Intravital Microscopy: Image neutrophil trafficking in cremaster muscle venules. HS1 deficiency reduces rolling velocity by 30% (P < 0.05) .

• Cytokine Profiling: Use Luminex assays to link HS1 status to IL-6/TNF-α levels .

Why does HS1 overexpression yield conflicting oncogenic outcomes?

Methodological Answer:

• Cell Type Dependence: HS1 enhances migration in SK-OV-3 ovarian cells but inhibits it in non-invasive lines like NOS2 .

• Expression Level Thresholds: Titrate HS1 cDNA concentrations; beyond 2 µg/mL, cytotoxic effects emerge .

• Post-Translational Modifications: Overexpressed HS1 may lack phosphorylation, altering functional readouts .

Resolution: Use inducible promoters (e.g., Tet-On) to control expression levels temporally .

How can I map HS1’s interactome in activated lymphocytes?

Methodological Answer:

• Co-IP/MS: Immunoprecipitate HS1 from activated T cells and identify partners via mass spectrometry. Known interactors include Vav1, Lck, and Arp2/3 .

• Proximity Ligation Assay (PLA): Visualize HS1-Vav1 complexes in situ using Duolink® probes .

• BioID: Express HS1-BirA* fusion proteins to capture transient interactions during IS formation .